MicroRNAs as therapeutic targets for ischemic stroke

    公开(公告)号:US11591597B2

    公开(公告)日:2023-02-28

    申请号:US17049041

    申请日:2019-04-18

    Abstract: The present invention includes methods for detecting and reducing or inhibiting ischemic stroke in a mammal, the method comprising: (a) selecting microRNAs to downregulate selected from the group consisting of hsa-miR-96-5p, hsa-miR-99a-5p, hsa-miR-122-5p, hsa-miR-186-5p, hsa-miR-211-5p, hsa-mir-760, PC-3p-57664, or PC-5p-12969, (b) selecting microRNAs to upregulate selected from the group consisting of ggo-miR-139, hsa-miR-30d-5p, hsa-miR-22-3p, hsa-miR-23a-3p, mmu-miR-5124a, mmu-mir-6240-5p, PC-3p-32463, or PC-5p-211, and combinations thereof, and (c) administering an agent that: downregulates that targets in (a), upregulates the targets in (b), or both, to the subject in an amount sufficient to reduce or inhibit ischemic stroke in the mammal. The present invention also includes the detection of the markers for use with stroke patients.

    MicroRNA-455-3p as a peripheral biomarker for Alzheimer's disease

    公开(公告)号:US11492669B2

    公开(公告)日:2022-11-08

    申请号:US16630068

    申请日:2018-07-12

    Abstract: The present invention includes a method for identifying an Alzheimer's disease (AD) patient prior to reaching clinical disease classification, comprising: obtaining a dataset associated with a blood, serum, or plasma sample from the patient, wherein the dataset comprises data representing the level of one or more microRNA biomarkers in the blood, serum, or plasma sample; assessing the dataset for a presence or an increase in an amount of miRNA-455-3p; determining the likelihood that the patient will develop AD patient prior to reaching clinical disease classification by detecting the presence or the increase in miRNA-455-3p to produce a score that is indicative of a likelihood of developing AD, wherein a higher score relative to a healthy control indicates that the patient is likely to have the prognosis for transitioning to classified AD, wherein the healthy control is derived from a non-AD patient with no clinical evidence of AD.

Patent Agency Ranking